|
Jul 23
|
HARMONY BIOSCIENCES TO REPORT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 6, 2024
|
|
Jul 16
|
MannKind Corporation (MNKD) Hit a 52 Week High, Can the Run Continue?
|
|
Jul 12
|
Inovio (INO) Soars 19.0%: Is Further Upside Left in the Stock?
|
|
Jun 25
|
HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT)
|
|
Jun 24
|
HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY
|
|
Jun 21
|
Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?
|
|
May 4
|
Results: Harmony Biosciences Holdings, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
|
|
May 3
|
Harmony Biosciences Holdings First Quarter 2024 Earnings: EPS Beats Expectations
|
|
May 1
|
Looking for a Growth Stock? 3 Reasons Why Harmony Biosciences (HRMY) is a Solid Choice
|
|
May 1
|
HRMY or TECH: Which Is the Better Value Stock Right Now?
|
|
May 1
|
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q1 2024 Earnings Call Transcript
|
|
Apr 30
|
Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript
|
|
Apr 30
|
Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View
|
|
Apr 30
|
Harmony Biosciences Exceeds Analyst Revenue Forecasts While Aligning with EPS Projections in Q1 2024
|
|
Apr 30
|
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
|
|
Apr 30
|
Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets
|
|
Apr 16
|
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024
|
|
Apr 11
|
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST
|
|
Apr 3
|
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME
|
|
Mar 26
|
HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
|